New Stock News | CanuBio submits application to Hong Kong Stock Exchange

According to the disclosure by the Hong Kong Stock Exchange on January 25, Conno Pharmaceuticals Limited (Conno Bio) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Guotou Securities International as its exclusive sponsor. The prospectus shows that Conno Bio is a biopharmaceutical company specializing in mitochondrial medicine and health products, with business covering research and development, drug production, and commercialization. The company focuses on diseases caused by mitochondrial dysfunction, and is dedicated to scientific research applying NAD+ to cardiovascular diseases, neurodegenerative diseases, reproductive health, aging, and other areas.